Our Pipeline
The surest path to clinical, regulatory, and commercial success starts with validated biology. That’s why we’re focused on acquiring and developing product candidates that possess a clear mechanism of action and that aim to address diseases with well-understood pathophysiology and significant unmet medical need. We believe that targeting the causal biology of a disease provides the highest probability of dramatically improving the lives of patients.
With this approach, we’ve built a broad and sustainable pipeline of product candidates with the potential to change the odds for patients with rare diseases in the areas of complement dysregulation and hematology.
Robust pipeline with significant potential for value creation
| Molecule | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| RLYB116 C5 Inhibitor Affibody®-ABD Fusion | Diseases of complement dysregulation | |||||
| RLYB332 Matriptase-2 Inhibitor Monoclonal Antibody | Diseases of iron overload and severe anemias | |||||
| RLYB114 C5 Inhibitor Pegylated Affibody® | Ophthalmological diseases of complement dysregulation | |||||
| Undisclosed | Undisclosed metabolic disease | Partnership with  |
||||
| C5: Complement component 5; ABD: Albumin-binding domain; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1 | ||||||
Partnerships
Finding treatments for rare disease isn’t about us. It’s about all of us.
If you’re looking to accelerate the development of a product candidate that is aligned with Rallybio’s mission, please contact us at [email protected].